South Korea’s largest private equity firm Hahn & Company has signed definitive agreements with Haelyung Hwang, founder and CEO of medical device maker Lutronic to acquire all remaining shares of the company for a total consideration of KRW957.0 billion ($735.9 million).

South Korea’s largest private equity firm Hahn & Company (Hahn & Co) has signed definitive agreements with Haelyung Hwang, founder and CEO of medical device maker Lutronic to acquire all remaining shares of the Company for a total consideration of KRW957.0 billion ($735.9 million).

Established in 1997, Lutronic is a global maker of aesthetic medical devices with revenues of over KRW264 billion in 2022. The Company has a rapidly growing global presence with 40% of revenues from the United States and 35% from Europe and the Middle East.

Lutronic represent the 34th investment in Korean businesses by Hahn & Co, with the firm having invested over $27 billion to date.